STERIS-Will Applied Sterilization Growth Help STE Beat Q4 Earnings Estimates?

Core Viewpoint - STERIS plc (STE) is set to release its fourth-quarter fiscal 2025 results on May 14, with expectations of revenue growth and increased earnings per share (EPS) compared to the previous year [1][2]. Financial Performance - The Zacks Consensus Estimate for revenues is $1.48 billion, reflecting a 4.2% increase from the prior year [2]. - The Zacks Consensus Estimate for EPS is$ 2.58, indicating a year-over-year increase of 7.1% [2]. - In the last reported quarter, STERIS posted adjusted EPS of $2.32, matching the Zacks Consensus Estimate, with an average surprise of 0.61% over the last four quarters [1][3]. Segment Analysis - **Healthcare**: Growth in consumables and services is expected to continue, driven by increased procedure volumes in the U.S. and market share gains [4]. The revenue for Healthcare capital equipment is projected to improve by 4.1% year-over-year [6]. - **Applied Sterilization Technologies (AST)**: Organic revenue growth is anticipated, with a projected increase of 9% year-over-year for this segment [7][8]. Despite previous declines in capital equipment shipments, demand in bioprocessing is expected to contribute positively [7]. - **Life Sciences**: This segment may see a revenue decline of 1.5% year-over-year, as strong growth in consumables and services is offset by a decrease in capital equipment revenue [9]. Estimate Revision Trend - Earnings estimates for STERIS have remained stable at$ 2.58 per share over the past 60 days, indicating confidence in the upcoming results [3]. Earnings ESP and Zacks Rank - STERIS has an Earnings ESP of 0.00%, suggesting a lower likelihood of beating earnings expectations [11]. The company currently holds a Zacks Rank of 3 (Hold) [11].